NASDAQ · IDYA

IDEAYA Biosciences, Inc.

$36.77 +$1.37 (+3.87%) 1D After hours

Key Metrics

$3.41B
Market cap
P/E · TTM
$225.27M
Revenue · TTM
−$140.06M
Net income
EPS · TTM $-1.59
Dividend yield
Free cash flow −$87.93M
Beta · 1Y 1.08
EBITDA · TTM −$180.68M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 9
    The stock moved -10.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 9
  • Jun 8
    The stock moved +11.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 8

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$3.41B
Enterprise value
Shares outstanding96.3M
52-wk range$22.09 – $40.58
Avg volume · 20D695.4K
Net cash
Book value / share$10.61
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About IDEAYA Biosciences, Inc.
IPO dateMay 23, 2019
Employees145

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S15.13
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -81.4%
Net -62.2%
FCF -39.0%
ROE / ROIC -14.0% · —

Financial Health

Current ratio10.74
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$631.28M

Cash Flow · TTM

Operating CF −$85.93M
Capex −$2.01M
Free cash flow −$87.93M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

21.2
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings